Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Results presented here showed patients who had significant weight loss prior to total hip arthroplasty with use of a GLP-1 ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

MONDAY, March 3, 2025 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) ...

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Researchers have found in a new study that Use of GLP-1 receptor agonists before pregnancy was associated with reduced risks ...